Douglas J. Williamson - 14 Feb 2022 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Reporting relationship: Chief Medical Officer
Issuer ticker: AVDL
Reported as of: 14 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Feb 2022, 15:40:17 UTC
Next SEC filing: 13 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Jerad G. Seurer, as Attorney-in-Fact

Key filing fact

Douglas J. Williamson filed Form 4 for AVADEL PHARMACEUTICALS PLC (AVDL) on 16 Feb 2022.

Key facts

This page summarizes Douglas J. Williamson's Form 4 filing for AVADEL PHARMACEUTICALS PLC (AVDL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Feb 2022, 15:40.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVDL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +275,000
Change %
Price: $0.000000
Shares after: 275,000
Date: 14 Feb 2022
Ownership: Direct
Underlying class: ADSs
Underlying amount: 275,000
Exercise price: $6.60
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Options become exercisable as to 68,750 ADSs on each of the first four anniversaries after the 2/14/2022 grant date.

Footnote F2

The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.